Company Profile
Vertex Pharmaceuticals Incorporated Stock Price, News & Analysis
- Ticker:
- VRTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
479.00 USD (+0.34%)
Close
Last updated: July 27, 2026
108B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, VRTX closed up 0.34% at $479.00. No new same-company headline was identified in the current news window.
Company overview
Business overview
Vertex Pharmaceuticals is a global biotechnology company best known for its leadership in cystic fibrosis. The company has expanded beyond CF into gene editing, pain, and other high-value disease areas, making it one of the most important growth stories in biotech.
Geographic Base and Sector Classification
Vertex is headquartered in the United States and listed on NASDAQ. It has a global commercial footprint and a premium biotech profile.
Business Model Characteristics
The company generates value from blockbuster product sales, disciplined R&D reinvestment, and a pipeline that extends beyond its core franchise. Investors watch CF execution, pipeline expansion, and whether new programs can preserve growth duration.
Position Within the Biotechnology Landscape
Vertex occupies the top tier of biotechnology because it combines commercial strength with innovation depth. It is less binary than a development-stage stock, but its pipeline still matters a great deal.
Future catalysts
Vertex's catalysts are ALYFTREK label expansion across the CF franchise and suzetrigine's pain filings and Phase 3 progression. The market will care about whether CF can keep compounding while the pain program turns into a second growth engine, because that is what keeps the long-duration story intact.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
- 03
- 04
- 05
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS · Source: Krystal Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated (VRTX) most recently closed at 479.00 USD, a +0.34% move versus the previous session.
What is the market cap of Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated currently has a market capitalization of 108B USD on BioPharmSignal.
What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals is a global biotechnology company best known for its leadership in cystic fibrosis. The company has expanded beyond CF into gene editing, pain, and other high-value disease areas, making it one of the most important growth stories in biotech.
On which exchange is VRTX stock listed?
Vertex Pharmaceuticals Incorporated (VRTX) is associated with NASDAQ, United States, Biopharma.
What is Vertex?
Vertex's catalysts are ALYFTREK label expansion across the CF franchise and suzetrigine's pain filings and Phase 3 progression.
Which conditions is Vertex Pharmaceuticals Incorporated targeting with Vertex?
Vertex's catalysts are ALYFTREK label expansion across the CF franchise and suzetrigine's pain filings and Phase 3 progression.
How does Vertex Pharmaceuticals Incorporated describe recent progress with Vertex?
Vertex's catalysts are ALYFTREK label expansion across the CF franchise and suzetrigine's pain filings and Phase 3 progression.
What is Pharmaceuticals?
Vertex Pharmaceuticals is a global biotechnology company best known for its leadership in cystic fibrosis.